Epilepsy patients get continued access to brivaracetam through compassionate program
NCT ID NCT03532516
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides brivaracetam (Briviact) to epilepsy patients who were already taking it in earlier studies, bridging the gap until the drug is commercially available. Patients continue their individual doses, up to 200 mg per day, with adjustments based on seizure control and side effects. Only patients who have already shown benefit and whose doctors agree that other treatments may not be suitable are eligible.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Brivaracetam (Briviact)
- What this could lead to
- If successful, this program could provide continuous seizure control for epilepsy patients who have already benefited from brivaracetam in prior studies.
- What could go wrong
- This is a compassionate use program, not a formal trial, so results are not systematically collected. It only includes patients already on the drug, so benefits may not apply to others.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPSY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can MRI reveal the Brain's response to deep brain stimulation?
- Can community hospitals in zambia master severe disease care?
- Can mindfulness rewire the mind to lift depression in epilepsy?
- A break from seizure pills: could less medication mean better living?
- Can invisible electric fields quiet the Brain's seizure signals?
- Can a new drug tame severe childhood epilepsy?